Effects of hypolipidemic drugs nafenopin and clofibrate on phenotypic expression and cell death (apoptosis) in altered foci of rat liver.
Phenotypically altered liver foci were produced in female Wistar rats by a single dose of N-nitrosomorpholine followed by promotion with phenobarbital (PB) for 20 or 28 weeks. Then treatment was changed to either hexachlorocyclohexane (HCH), or cyproterone acetate (CPA), or nafenopin (Naf) or clofibrate (Clof), two hypolipidemic drugs. Foci were identified by a positive reaction for gamma-glutamyl-transpeptidase (GGT) and other cytological markers. HCH and CPA could substitute for PB as foci promoters; in contrast, Naf and Clof decreased expression of GGT in foci resulting in a decline of number and area of detectable foci, effects particularly pronounced with Naf. Immunohistochemical investigations of serial sections revealed that Naf also reduced expression of the altered phenotype when cytochrome P450-PB and pyruvate kinase (type L) were used as foci markers, but not when glutathione-S-transferase B (GST-B) was used. Thus, the number of foci with enhanced GST-B did not decline significantly after the change from PB to Naf treatment. Furthermore, the reduction of GGT and the decrease of foci number during Naf treatment were not associated with increased evidence of cell death by apoptosis in foci, in contrast to the situation after PB withdrawal. These findings strongly suggest that the disappearance of GGT-positive foci after Naf is due to a phenotypic change resulting in a suppression of GGT expression rather than to physical elimination of foci.
Institut für Tumorbiologie-Krebsforschung, Universität Wien, Austria.
U
U
Gerbracht
W
W
Bursch
P
P
Kraus
B
B
Putz
M
M
Reinacher
I
I
Timmermann-Trosiener
R
R
Schulte-Hermann
D000818:Animals; D001835:Body Weight; D002273:Carcinogens; D002470:Cell Survival / Q000187:drug effects; D002994:Clofibrate / Q000494:pharmacology*; D003534:Cyproterone / Q000031:analogs & derivatives / Q000633:toxicity; D017373:Cyproterone Acetate; D005260:Female; D005982:Glutathione Transferase / Q000378:metabolism; D001556:Hexachlorocyclohexane / Q000633:toxicity; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced* / Q000473:pathology; D009255:Nafenopin / Q000494:pharmacology*; D009602:Nitrosamines / Q000633:toxicity; D009929:Organ Size; D010634:Phenobarbital / Q000633:toxicity; D010641:Phenotype; D011230:Precancerous Conditions / Q000139:chemically induced* / Q000473:pathology; D011422:Propionates / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D002273:Carcinogens; D009602:Nitrosamines; D011422:Propionates; D009255:Nafenopin; C002741:N-nitrosomorpholine; D017373:Cyproterone Acetate; D001556:Hexachlorocyclohexane; D003534:Cyproterone; D005982:Glutathione Transferase; D002994:Clofibrate; D010634:Phenobarbital